Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 11

1.

Comparing CAR T-cell toxicity grading systems: application of the ASTCT grading system and implications for management.

Pennisi M, Jain T, Santomasso BD, Mead E, Wudhikarn K, Silverberg ML, Batlevi Y, Shouval R, Devlin SM, Batlevi C, Brentjens RJ, Dahi PB, Diamonte C, Giralt S, Halton EF, Maloy M, Palomba ML, Sanchez-Escamilla M, Sauter CS, Scordo M, Shah G, Park JH, Perales MA.

Blood Adv. 2020 Feb 25;4(4):676-686. doi: 10.1182/bloodadvances.2019000952.

2.

Impact and safety of chimeric antigen receptor T cell therapy in older, vulnerable patients with relapsed/refractory large b-cell lymphoma.

Lin RJ, Lobaugh SM, Pennisi M, Chan HT, Batlevi Y, Ruiz JD, Elko TA, Maloy MA, Batlevi CL, Dahi PB, Giralt SA, Hamlin PA, Mead E, Noy A, Palomba ML, Santomasso BD, Sauter CS, Scordo M, Shah GL, Korc-Grodzicki B, Kim SJ, Silverberg ML, Brooklyn CA, Devlin SM, Perales MA.

Haematologica. 2020 Feb 20. pii: haematol.2019.243246. doi: 10.3324/haematol.2019.243246. [Epub ahead of print] No abstract available.

3.

MRI radiomic features are associated with survival in melanoma brain metastases treated with immune checkpoint inhibitors.

Bhatia A, Birger M, Veeraraghavan H, Um H, Tixier F, McKenney AS, Cugliari M, Caviasco A, Bialczak A, Malani R, Flynn J, Zhang Z, Yang TJ, Santomasso BD, Shoushtari AN, Young RJ.

Neuro Oncol. 2019 Dec 17;21(12):1578-1586. doi: 10.1093/neuonc/noz141.

PMID:
31621883
4.

BCMA-Targeted CAR T-cell Therapy plus Radiotherapy for the Treatment of Refractory Myeloma Reveals Potential Synergy.

Smith EL, Mailankody S, Staehr M, Wang X, Senechal B, Purdon TJ, Daniyan AF, Geyer MB, Goldberg AD, Mead E, Santomasso BD, Landa J, Rimner A, Riviere I, Landgren O, Brentjens RJ.

Cancer Immunol Res. 2019 Jul;7(7):1047-1053. doi: 10.1158/2326-6066.CIR-18-0551. Epub 2019 May 21.

PMID:
31113804
5.

Reply.

Lee DW, Mead E, Santomasso BD, Turtle CJ, Grupp SA, Neelapu SS.

Biol Blood Marrow Transplant. 2019 Jun;25(6):e211-e212. doi: 10.1016/j.bbmt.2019.03.019. Epub 2019 Mar 23. No abstract available.

PMID:
30910604
6.

ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells.

Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, Maus MV, Park JH, Mead E, Pavletic S, Go WY, Eldjerou L, Gardner RA, Frey N, Curran KJ, Peggs K, Pasquini M, DiPersio JF, van den Brink MRM, Komanduri KV, Grupp SA, Neelapu SS.

Biol Blood Marrow Transplant. 2019 Apr;25(4):625-638. doi: 10.1016/j.bbmt.2018.12.758. Epub 2018 Dec 25. Review.

7.

Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia.

Santomasso BD, Park JH, Salloum D, Riviere I, Flynn J, Mead E, Halton E, Wang X, Senechal B, Purdon T, Cross JR, Liu H, Vachha B, Chen X, DeAngelis LM, Li D, Bernal Y, Gonen M, Wendel HG, Sadelain M, Brentjens RJ.

Cancer Discov. 2018 Aug;8(8):958-971. doi: 10.1158/2159-8290.CD-17-1319. Epub 2018 Jun 7.

8.

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.

Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, Chau I, Ernstoff MS, Gardner JM, Ginex P, Hallmeyer S, Holter Chakrabarty J, Leighl NB, Mammen JS, McDermott DF, Naing A, Nastoupil LJ, Phillips T, Porter LD, Puzanov I, Reichner CA, Santomasso BD, Seigel C, Spira A, Suarez-Almazor ME, Wang Y, Weber JS, Wolchok JD, Thompson JA; National Comprehensive Cancer Network.

J Clin Oncol. 2018 Jun 10;36(17):1714-1768. doi: 10.1200/JCO.2017.77.6385. Epub 2018 Feb 14.

9.

T cells presenting viral antigens or autoantigens induce cytotoxic T cell anergy.

Blachère NE, Orange DE, Gantman EC, Santomasso BD, Couture GC, Ramirez-Montagut T, Fak J, O'Donovan KJ, Ru Z, Parveen S, Frank MO, Moore MJ, Darnell RB.

JCI Insight. 2017 Nov 2;2(21). pii: 96173. doi: 10.1172/jci.insight.96173.

10.

T cells targeting a neuronal paraneoplastic antigen mediate tumor rejection and trigger CNS autoimmunity with humoral activation.

Blachère NE, Orange DE, Santomasso BD, Doerner J, Foo PK, Herre M, Fak J, Monette S, Gantman EC, Frank MO, Darnell RB.

Eur J Immunol. 2014 Nov;44(11):3240-51. doi: 10.1002/eji.201444624.

11.

A T-cell receptor associated with naturally occurring human tumor immunity.

Santomasso BD, Roberts WK, Thomas A, Williams T, Blachère NE, Dudley ME, Houghton AN, Posner JB, Darnell RB.

Proc Natl Acad Sci U S A. 2007 Nov 27;104(48):19073-8.

Supplemental Content

Loading ...
Support Center